Candel melaporkan manfaat DFS Fase 3 untuk aglatimagene besadenovec pada kanker prostat

Data tindak lanjut yang diperpanjang dari uji coba Fase 3 yang diacak (n=745) menunjukkan aglatimagene besadenovec plus prodrug plus radioterapi standar secara signifikan meningkatkan kelangsungan hidup bebas penyakit spesifik kanker prostat dibandingkan plasebo (HR 0.61, p=0.0031). Perusahaan juga mengamati waktu yang lebih lama hingga terapi penyelamatan, kegagalan biokimia, dan metastasis pada kelompok aktif.

Fakta utama

Diajukan: 15 Mei 2026, 20.13
Peristiwa: Hasil topline
Arah: Positif
Perusahaan: CADLCandel Therapeutics
Aset: CAN-2409
Sumber: SEC 8-K
Keyakinan: Bersumber
p: 0.0031
CI: 0.44 - 0.85
HR: 0.61
median tindak lanjut: 58.0 bulan

Kutipan sumber

EX-99.1 2 d106447dex991.htm EX-99.1 EX-99.1 AUA Investor Call Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer May 15, 2026 NASDAQ: CADL Exhibit 99.1 Forward-looking statements This Presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this Presentation, including express or implied statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market size, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “pla

SEC 8-K